ATE364044T1 - 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit - Google Patents

5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit

Info

Publication number: ATE364044T1
Authority: AT; Austria
Prior art keywords: obesity; treatment; diabetes; receptor agonists; sup
Prior art date: 2003-06-26

Application number

AT04740057T

Other languages

English (en)

Inventor

Toby Jonathan Blench

Paul Hebeisen

Hans Richter

Stephan Roever

Original Assignee

Hoffmann La Roche

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-26

Filing date

2004-06-18

Publication date

2007-06-15

2004-06-18 Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE364044T1 publication Critical patent/ATE364044T1/de

Links

208000008589 Obesity Diseases 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title 1
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
150000002148 esters Chemical class 0.000 abstract 1
150000004885 piperazines Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)

AT04740057T 2003-06-26 2004-06-18 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit ATE364044T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0314967.1A GB0314967D0 (en)	2003-06-26	2003-06-26	Piperazine derivatives

Publications (1)

Publication Number	Publication Date
ATE364044T1 true ATE364044T1 (de)	2007-06-15

Family

ID=27637436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04740057T ATE364044T1 (de)	2003-06-26	2004-06-18	5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit

Country Status (14)

Country	Link
US (1)	US7208494B2 (de)
EP (1)	EP1641796B1 (de)
JP (1)	JP4362511B2 (de)
KR (1)	KR100756113B1 (de)
CN (1)	CN100400538C (de)
AT (1)	ATE364044T1 (de)
AU (1)	AU2004251847B2 (de)
BR (1)	BRPI0411936A (de)
CA (1)	CA2530308C (de)
DE (1)	DE602004006869T2 (de)
ES (1)	ES2287741T3 (de)
GB (1)	GB0314967D0 (de)
MX (1)	MXPA05013856A (de)
WO (1)	WO2005000849A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1792629A4 (de)	2004-08-25	2010-08-25	Takeda Pharmaceutical	Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
AU2006243243B2 (en) *	2005-05-03	2009-05-14	F. Hoffmann-La Roche Ag	Tetracyclic azapyrazinoindolines as 5-HT2 ligands
WO2006125179A1 (en) *	2005-05-19	2006-11-23	Xenon Pharmaceuticals Inc.	Tricyclic compounds and their uses as therapeutic agents
WO2007025144A1 (en) *	2005-08-24	2007-03-01	University Of Illinois - Chicago	5-ht2c receptor agonists as anorectic agents
RU2417226C2 (ru) *	2005-11-18	2011-04-27	Ф.Хоффманн-Ля Рош Аг	Производные азаиндол-2-карбоксамида
WO2007065820A1 (en) *	2005-12-09	2007-06-14	F. Hoffmann-La Roche Ag	Tricyclic amide derivatives useful for treating obesity
EP2727585A1 (de)	2006-05-16	2014-05-07	Takeda Pharmaceutical Company Limited	In-vivo Screening-Methode
US20100280505A1 (en) *	2006-07-04	2010-11-04	Bracco Imaging S.P.A.	Device for Localized Thermal Ablation of Biological Tissue, Particularly Tumoral Tissues or the Like
EP2216023A4 (de)	2007-11-15	2013-03-13	Takeda Pharmaceutical	Kondensiertes pyridinderivat und seine verwendung
EP2348857B1 (de)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Neue cyclische benzimidazolderivate als antidiabetika
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
JPWO2011071136A1 (ja)	2009-12-11	2013-04-22	アステラス製薬株式会社	線維筋痛症治療剤
JP5810099B2 (ja)	2010-02-04	2015-11-11	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅＢｏａｒｄＯｆＴｒｕｓｔｅｅｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＩｌｌｉｎｏｉｓ	５−ｈｔ（２ｂ）受容体でアンタゴニスト活性を有する高選択性５−ｈｔ（２ｃ）受容体アゴニスト
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20130267500A1 (en)	2010-09-01	2013-10-10	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
MX348131B (es)	2011-02-25	2017-05-26	Merck Sharp & Dohme	Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use
WO2016123164A1 (en)	2015-01-29	2016-08-04	The Board Of Trustees Of The University Of Illinois	Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
JPWO2019131902A1 (ja)	2017-12-27	2020-12-10	武田薬品工業株式会社	腹圧性尿失禁および便失禁の治療薬
WO2023137634A1 (zh) *	2022-01-19	2023-07-27	上海奕拓医药科技有限责任公司	三并环化合物、其制备、药物组合物及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3317524A (en) *	1965-02-04	1967-05-02	American Home Prod	Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
CA1247547A (en) *	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
US4844839A (en) *	1984-09-04	1989-07-04	Manchak Frank	In situ treatment and analysis of wastes
US4776409A (en) *	1984-09-04	1988-10-11	Manchak Frank	Insitu waste impoundment treating apparatus and method of using same
CA1328881C (en) *	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
US5246960A (en) *	1984-12-21	1993-09-21	Hoffmann-La Roche Inc.	Oxetanones
CA1270837A (en) *	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
AU583656B2 (en) *	1985-08-26	1989-05-04	Frank Manchak Jr.	In situ hazardous waste treating apparatus and method of using same
CA2035972C (en) *	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0572863A1 (de)	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
PL310443A1 (en) *	1993-03-01	1995-12-11	Merck Sharp & Dohme	Derivatives of pyrolo-pyridine
TW334423B (en)	1993-10-22	1998-06-21	Hoffmann La Roche	Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (de)	1993-10-22	1996-02-11	Hoffmann La Roche
WO1998030548A1 (en)	1997-01-13	1998-07-16	Yamanouchi Pharmaceutical Co., Ltd.	5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES
US6004996A (en) *	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
DE69916288T2 (de)	1998-08-14	2005-03-24	F. Hoffmann-La Roche Ag	Lipasehemmer und chitosan enthaltende arzneimittel
BR9912980B1 (pt)	1998-08-14	2013-10-22		Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
GB9819019D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds II
GB9819032D0 (en) *	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds IV
GB9819020D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds III
GB9819033D0 (en) *	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds VI
GB9819035D0 (en) *	1998-09-01	1998-10-28	Cerebrus Res Ltd	Chemical compounds VII
GB9820767D0 (en)	1998-09-23	1998-11-18	Cerebrus Ltd	Chemical compounds VIII
IL143323A0 (en)	1998-12-17	2002-04-21	American Home Prod	2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists
GB9902047D0 (en) *	1999-01-29	1999-03-17	Cerebrus Ltd	Chemical compounds XI
GB9918965D0 (en)	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxi
GB9918962D0 (en) *	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxii
EP1132389A1 (de)	2000-03-06	2001-09-12	Vernalis Research Limited	Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
US6635598B2 (en) *	2000-04-20	2003-10-21	Indian Petrochemicals Corporation Limited	Stable and selective dehydrogenation catalyst and a process for the preparation thereof
DE60113865T2 (de) *	2000-07-31	2006-07-20	Vernalis Research Ltd., Winnersh	Piperazin derivate
EP1347979B1 (de) *	2000-12-27	2007-08-08	F. Hoffmann-La Roche Ag	Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
GB0202015D0 (en) *	2002-01-29	2002-03-13	Hoffmann La Roche	Piperazine Derivatives

2003
- 2003-06-26 GB GBGB0314967.1A patent/GB0314967D0/en not_active Ceased
2004
- 2004-06-18 WO PCT/EP2004/006612 patent/WO2005000849A1/en not_active Ceased
- 2004-06-18 CA CA002530308A patent/CA2530308C/en not_active Expired - Fee Related
- 2004-06-18 EP EP04740057A patent/EP1641796B1/de not_active Expired - Lifetime
- 2004-06-18 BR BRPI0411936-3A patent/BRPI0411936A/pt not_active IP Right Cessation
- 2004-06-18 JP JP2006515997A patent/JP4362511B2/ja not_active Expired - Fee Related
- 2004-06-18 KR KR1020057024843A patent/KR100756113B1/ko not_active Expired - Fee Related
- 2004-06-18 MX MXPA05013856A patent/MXPA05013856A/es unknown
- 2004-06-18 AU AU2004251847A patent/AU2004251847B2/en not_active Ceased
- 2004-06-18 DE DE602004006869T patent/DE602004006869T2/de not_active Expired - Lifetime
- 2004-06-18 CN CNB2004800179181A patent/CN100400538C/zh not_active Expired - Fee Related
- 2004-06-18 AT AT04740057T patent/ATE364044T1/de not_active IP Right Cessation
- 2004-06-18 ES ES04740057T patent/ES2287741T3/es not_active Expired - Lifetime
- 2004-06-25 US US10/876,954 patent/US7208494B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE602004006869D1 (de)	2007-07-19
CA2530308A1 (en)	2005-01-06
KR20060028773A (ko)	2006-04-03
BRPI0411936A (pt)	2006-08-29
EP1641796B1 (de)	2007-06-06
CN1812989A (zh)	2006-08-02
CN100400538C (zh)	2008-07-09
AU2004251847B2 (en)	2007-08-23
US20050026925A1 (en)	2005-02-03
KR100756113B1 (ko)	2007-09-05
JP2007506667A (ja)	2007-03-22
ES2287741T3 (es)	2007-12-16
CA2530308C (en)	2009-06-09
WO2005000849A1 (en)	2005-01-06
AU2004251847A1 (en)	2005-01-06
JP4362511B2 (ja)	2009-11-11
MXPA05013856A (es)	2006-02-28
US7208494B2 (en)	2007-04-24
EP1641796A1 (de)	2006-04-05
DE602004006869T2 (de)	2008-02-07
GB0314967D0 (en)	2003-07-30

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1641796

Country of ref document: EP

2012-03-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE602004006869D1 (de)	2007-07-19	5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
ATE327977T1 (de)	2006-06-15	Tetrahydrochinolin-derivate als crth2 antagonisten
BR0311541A (pt)	2006-06-06	indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
TNSN04136A1 (en)	2007-03-12	Aza-arylpiperazines
ATE384058T1 (de)	2008-02-15	Thiazolderivate
EA200700118A1 (ru)	2007-08-31	Амидосоединения и их применение в качестве лекарственных средств
DE602004012858D1 (de)	2008-05-15	2-aminobenzothiazole als cb1 rezeptor inverse agonisten
SE0403006D0 (sv)	2004-12-09	New compounds
MY136761A (en)	2008-11-28	Oxazol derivatives
UY26291A1 (es)	2001-03-16	Compuestos químicos xxii
NO20090328L (no)	2009-01-26	Nye forbindelser 385
MX2007008614A (es)	2007-09-11	Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
EA200601802A1 (ru)	2007-02-27	Производные морфолина
SE0201544D0 (sv)	2002-05-17	Novel compounds and thier use
TW200508207A (en)	2005-03-01	New benzimidazole derivatives
IS8485A (is)	2006-05-26	Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ATE386725T1 (de)	2008-03-15	Heterocyclylverbindungen
SE0403171D0 (sv)	2004-12-23	New compounds
ATE507212T1 (de)	2011-05-15	Morpholine als 5ht2c-agonisten
MY143568A (en)	2011-05-31	11b-hsd1 inhibitors for the treatment of diabetes
SE0301699D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
SE0401763D0 (sv)	2004-07-05	Compounds